Every year the experts in transcatheter heart valves therapies come together in London to share the latest developments in the field at the London Valves conference. This year’s edition showed more novelties and had more attendees than ever before. Our team was happy to meet all the stakeholders from the industry and physicians that are using Materialise Mimics today in their research of new technologies and planning of novel cases. We look back at the highlights and the lessons learned.
Mitral Valve Therapies Are Evolving Fast
Over the last years, various transcatheter mitral valve therapies have started developments and many of the big medical device companies have invested heavily in acquiring and developing these treatments. The results of the first groups of patients being treated with these new technologies were presented. Experts pointed out that a detailed analysis of the anatomy is fundamental to select the right patients for a specific technology and planning each procedure carefully which is key for success to anticipate for paravalvular leakage and left ventricular outflow tract obstruction.
TAVI Moving to Lower Risk Patients
Transcatheter Aortic Valve Implantation (TAVI) has grown to an established treatment option for patients where the risk of surgery is too high. With the great results that are being achieved in these patients, the discussion arises to also introduce this minimal invasive treatment to lower risk patients. One of the points repeated many times in this discussion is how better planning can lower the current complication rates. The first trials in intermediate risk patients have started this year and look forward to next year to see how these results will contribute to the discussions.
What’s Next? Tricuspid Valve Therapies
The tricuspid valve was for years the forgotten valve of the heart. Not anymore, as dedicated sessions on the tricuspid valve revealed that new therapies are being developed and mitral valve therapies are being adapted to fit the tricuspid valve. Detailed imaging of the tricuspid valve remains challenging and developments from the medical imaging field will be crucial to allow accurate pre-procedural planning. Materialise is committed to continue to work on even better planning solutions for all these treatment challenges in the future. We’ll keep you posted via this blog.